Synthesis of novel ketoconazole derivatives as inhibitors of the human Pregnane X Receptor (PXR; NR1I2; also termed SXR, PAR)

Bhaskar C. Das, Ankanahlli V. Madhukumar, Jaime Anguiano, Sean Kim, Michael Sinz, Tatyana A. Zvyaga, Eoin C. Power, C. Robin Ganellin, Sridhar Mani

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

PXR, pregnane X receptor, in its activated state, is a validated target for controlling certain drug-drug interactions in humans. In this context, there is a paucity of inhibitors directed toward activated PXR. Using prior observations with ketoconazole as a PXR inhibitor, the target compound 3 was synthesized from (s)-glycidol with overall 56% yield. (+)-Glycidol was reacted with 4-bromophenol and potassium carbonate in DMF to yield the ring opened compound 6. This was then heated to reflux in benzene along with 2′, 4′-difluoroacetophenone and catalytic amount of para-toluene sulfonic acid to yield 8. The resultant acetal 8 was then functionalized using Palladium chemistry to yield the target compound 3. The activity of the compound was compared with ketoconazole and UCL2158H. However, in contrast with ketoconazole (IC50 ∼ 0.020 μM; ∼100% inhibition), 3 has negligible effects on inhibition of microsomal CYP450 (maximum ∼20% inhibition) at concentrations >40 μM. In vitro, micromolar concentration of ketoconazole is toxic to passaged human cell lines, while 3 does not exhibit cytotoxicity up to concentrations ∼100 μM (viability >85%). This is the first demonstration of a chemical analog of a PXR inhibitor that retains activity against activated PXR. Furthermore, in contrast with ketoconazole, 3 is less toxic in human cell lines and has negligible CYP450 activity.

Original languageEnglish (US)
Pages (from-to)3974-3977
Number of pages4
JournalBioorganic and Medicinal Chemistry Letters
Volume18
Issue number14
DOIs
StatePublished - Jul 15 2008

Fingerprint

Ketoconazole
glycidol
Derivatives
Poisons
Cells
Drug interactions
Cell Line
Acetals
Sulfonic Acids
Toluene
Palladium
Cytotoxicity
Benzene
Drug Interactions
Inhibitory Concentration 50
Demonstrations
pregnane X receptor
Pharmaceutical Preparations

Keywords

  • Analogs
  • Azole
  • Ketoconazole
  • Nuclear receptors
  • Pregnane X receptor
  • PXR

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Organic Chemistry
  • Drug Discovery
  • Pharmaceutical Science

Cite this

Synthesis of novel ketoconazole derivatives as inhibitors of the human Pregnane X Receptor (PXR; NR1I2; also termed SXR, PAR). / Das, Bhaskar C.; Madhukumar, Ankanahlli V.; Anguiano, Jaime; Kim, Sean; Sinz, Michael; Zvyaga, Tatyana A.; Power, Eoin C.; Ganellin, C. Robin; Mani, Sridhar.

In: Bioorganic and Medicinal Chemistry Letters, Vol. 18, No. 14, 15.07.2008, p. 3974-3977.

Research output: Contribution to journalArticle

Das, Bhaskar C. ; Madhukumar, Ankanahlli V. ; Anguiano, Jaime ; Kim, Sean ; Sinz, Michael ; Zvyaga, Tatyana A. ; Power, Eoin C. ; Ganellin, C. Robin ; Mani, Sridhar. / Synthesis of novel ketoconazole derivatives as inhibitors of the human Pregnane X Receptor (PXR; NR1I2; also termed SXR, PAR). In: Bioorganic and Medicinal Chemistry Letters. 2008 ; Vol. 18, No. 14. pp. 3974-3977.
@article{a038334f1fc34977a495bb23d2f4a3a2,
title = "Synthesis of novel ketoconazole derivatives as inhibitors of the human Pregnane X Receptor (PXR; NR1I2; also termed SXR, PAR)",
abstract = "PXR, pregnane X receptor, in its activated state, is a validated target for controlling certain drug-drug interactions in humans. In this context, there is a paucity of inhibitors directed toward activated PXR. Using prior observations with ketoconazole as a PXR inhibitor, the target compound 3 was synthesized from (s)-glycidol with overall 56{\%} yield. (+)-Glycidol was reacted with 4-bromophenol and potassium carbonate in DMF to yield the ring opened compound 6. This was then heated to reflux in benzene along with 2′, 4′-difluoroacetophenone and catalytic amount of para-toluene sulfonic acid to yield 8. The resultant acetal 8 was then functionalized using Palladium chemistry to yield the target compound 3. The activity of the compound was compared with ketoconazole and UCL2158H. However, in contrast with ketoconazole (IC50 ∼ 0.020 μM; ∼100{\%} inhibition), 3 has negligible effects on inhibition of microsomal CYP450 (maximum ∼20{\%} inhibition) at concentrations >40 μM. In vitro, micromolar concentration of ketoconazole is toxic to passaged human cell lines, while 3 does not exhibit cytotoxicity up to concentrations ∼100 μM (viability >85{\%}). This is the first demonstration of a chemical analog of a PXR inhibitor that retains activity against activated PXR. Furthermore, in contrast with ketoconazole, 3 is less toxic in human cell lines and has negligible CYP450 activity.",
keywords = "Analogs, Azole, Ketoconazole, Nuclear receptors, Pregnane X receptor, PXR",
author = "Das, {Bhaskar C.} and Madhukumar, {Ankanahlli V.} and Jaime Anguiano and Sean Kim and Michael Sinz and Zvyaga, {Tatyana A.} and Power, {Eoin C.} and Ganellin, {C. Robin} and Sridhar Mani",
year = "2008",
month = "7",
day = "15",
doi = "10.1016/j.bmcl.2008.06.018",
language = "English (US)",
volume = "18",
pages = "3974--3977",
journal = "Bioorganic and Medicinal Chemistry Letters",
issn = "0960-894X",
publisher = "Elsevier Limited",
number = "14",

}

TY - JOUR

T1 - Synthesis of novel ketoconazole derivatives as inhibitors of the human Pregnane X Receptor (PXR; NR1I2; also termed SXR, PAR)

AU - Das, Bhaskar C.

AU - Madhukumar, Ankanahlli V.

AU - Anguiano, Jaime

AU - Kim, Sean

AU - Sinz, Michael

AU - Zvyaga, Tatyana A.

AU - Power, Eoin C.

AU - Ganellin, C. Robin

AU - Mani, Sridhar

PY - 2008/7/15

Y1 - 2008/7/15

N2 - PXR, pregnane X receptor, in its activated state, is a validated target for controlling certain drug-drug interactions in humans. In this context, there is a paucity of inhibitors directed toward activated PXR. Using prior observations with ketoconazole as a PXR inhibitor, the target compound 3 was synthesized from (s)-glycidol with overall 56% yield. (+)-Glycidol was reacted with 4-bromophenol and potassium carbonate in DMF to yield the ring opened compound 6. This was then heated to reflux in benzene along with 2′, 4′-difluoroacetophenone and catalytic amount of para-toluene sulfonic acid to yield 8. The resultant acetal 8 was then functionalized using Palladium chemistry to yield the target compound 3. The activity of the compound was compared with ketoconazole and UCL2158H. However, in contrast with ketoconazole (IC50 ∼ 0.020 μM; ∼100% inhibition), 3 has negligible effects on inhibition of microsomal CYP450 (maximum ∼20% inhibition) at concentrations >40 μM. In vitro, micromolar concentration of ketoconazole is toxic to passaged human cell lines, while 3 does not exhibit cytotoxicity up to concentrations ∼100 μM (viability >85%). This is the first demonstration of a chemical analog of a PXR inhibitor that retains activity against activated PXR. Furthermore, in contrast with ketoconazole, 3 is less toxic in human cell lines and has negligible CYP450 activity.

AB - PXR, pregnane X receptor, in its activated state, is a validated target for controlling certain drug-drug interactions in humans. In this context, there is a paucity of inhibitors directed toward activated PXR. Using prior observations with ketoconazole as a PXR inhibitor, the target compound 3 was synthesized from (s)-glycidol with overall 56% yield. (+)-Glycidol was reacted with 4-bromophenol and potassium carbonate in DMF to yield the ring opened compound 6. This was then heated to reflux in benzene along with 2′, 4′-difluoroacetophenone and catalytic amount of para-toluene sulfonic acid to yield 8. The resultant acetal 8 was then functionalized using Palladium chemistry to yield the target compound 3. The activity of the compound was compared with ketoconazole and UCL2158H. However, in contrast with ketoconazole (IC50 ∼ 0.020 μM; ∼100% inhibition), 3 has negligible effects on inhibition of microsomal CYP450 (maximum ∼20% inhibition) at concentrations >40 μM. In vitro, micromolar concentration of ketoconazole is toxic to passaged human cell lines, while 3 does not exhibit cytotoxicity up to concentrations ∼100 μM (viability >85%). This is the first demonstration of a chemical analog of a PXR inhibitor that retains activity against activated PXR. Furthermore, in contrast with ketoconazole, 3 is less toxic in human cell lines and has negligible CYP450 activity.

KW - Analogs

KW - Azole

KW - Ketoconazole

KW - Nuclear receptors

KW - Pregnane X receptor

KW - PXR

UR - http://www.scopus.com/inward/record.url?scp=47149088622&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=47149088622&partnerID=8YFLogxK

U2 - 10.1016/j.bmcl.2008.06.018

DO - 10.1016/j.bmcl.2008.06.018

M3 - Article

C2 - 18583127

AN - SCOPUS:47149088622

VL - 18

SP - 3974

EP - 3977

JO - Bioorganic and Medicinal Chemistry Letters

JF - Bioorganic and Medicinal Chemistry Letters

SN - 0960-894X

IS - 14

ER -